Abstract: The invention provides means of diagnosing and treating microvascular angina (MVA). Diagnostic applications of intra-coronary guidewires are provided. Treatment of MVA patients with zibotentan is disclosed. The MVA patient can be identified and selected for treatment via the diagnostic applications provided.

Abstract: The objective of the current invention is the control of agricultural infestations based on alternative methods that are less aggressive to the environment and that are harmless to other invertebrates and to man; for instance biological control using bacterial strains belonging to species of the genera Bacillus, Brevibacillus and/or Paenibacillus. A first embodiment of the invention refers to compositions based on the systemic utilization of bacterial strains belonging to species of the genera Bacillus, Brevibacillus and/or Paenibacillus to protect plants by using the composition containing the above referred bacteria in wild-type, conjugated, mutant or transgenic forms and/or the substances produced by them. A second embodiment of the invention refers to a method of bioinsecticide application based on bacteria from the genera Bacillus, Brevibacillus and/or Paenibacillus.

Abstract: The objective of the current invention is the control of agricultural infestations based on alternative methods that are less aggressive to the environment and that are harmless to other invertebrates and to man; for instance biological control using bacterial strains belonging to species of the genera Bacillus, Brevibacillus and/or Paenibacillus. A first embodiment of the invention refers to compositions based on the systemic utilization of bacterial strains belonging to species of the genera Bacillus, Brevibacillus and/or Paenibacillus to protect plants by using the composition containing the above referred bacteria in wild-type, conjugated, mutant or transgenic forms and/or the substances produced by them. A second embodiment of the invention refers to a method of bioinsecticide application based on bacteria from the genera Bacillus, Brevibacillus and/or Paenibacillus.

Abstract: A method for determining the activity of a substance capable of altering the structure of a nucleic acid molecule from a first to a second state which is based upon the use of labelled nucleic acid molecules and/or complementary oligonucleotides. The label is a chemiluminescent molecule and a corresponding quencher molecule whose optical properties are different depending upon whether the nucleic acid molecule exist in said first or second state.

Abstract: The invention relates to a method for determining the activity of an enzyme or enediyne capable of altering the structure of a “substrate” nucleic acid from a first to a second state wherein the activity of the enzyme or enedyine is monitored using a chemiluminescent label that is either attached to the “substrate” nucleic acid or an oligonucleotide which is complementary thereto or the enzyme or enediyne product thereof.

Abstract: Use of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, as an inhibitor of at least one &bgr;-ketoacyl acyl carrier protein synthase operable in the fatty acid biosynthesis of endoparasites, which compound is of the general formula (I) where R1 is selected from the group consisting of hydrogen, alkyl, (cyano)alkylene, alkenyl, alkynyl, (alkoxy)alkylene, (alkoxy)alkenylene, (alkoxy)alkynylene, cycloalkyl, (cycloalkyl)alkylene, (cycloalkyl)alkenylene, (cycloalkyl)alkynylene, (hetero-cycle)alkylene, (heterocycle)alkenylene, (heterocycle)alkynylene, aryl, (aryl)alkylene, (aryl)alkenylene, (aryl)alkynylene, (arylcarbonylarylene)alkylene, (arylcarbonylarylene)alkenylene and (arylcarbonylarylene)alkynylene; R2 is alkyl or cycloalkyl; R3 is alkyl or cycloalkyl; and R4 is hydrogen or alkyl; including racemic mixtures and enantiomers of said compound when the latter is chiral, but excluding the racemic mixture of a chiral compound of formula (I) in which R1 is CH2═CH—C(CH3)&boxH